N-Cadherin Antibody / CDH2

Immunohistochemistry (FFPE): 1-2ug/ml for 30 minutes at RT

Optimal dilution of the recombinant CDH2 antibody should be determined by the researcher.

Recognizes a protein of ~140kDa, identified as N-Cadherin (NCAD), also known as CD325 and CDH2. NCAD is a member of the Cadherin superfamily, and consists of five extracellular repeats, a transmembrane domain and a cytoplasmic domain. CD325 deficient mice die at day 10 of gestation and embryos display major heart defects and malformed neural tubes and somites. Consistent with this, CD325 has been implicated in several aspects of cardiac development including the precardiac mesoderm, establishment of left-right symmetry and cardiac looping morphogenesis. Furthermore, CD325 is normally involved in inducing cell cycle arrest and its expression is frequently deregulated in cancer cells.Studies have linked N-cadherin to cancer metastasis by showing the aggressive tumor cells had preferentially turned on N-cadherin as opposed to E- or P-cadherin.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

Recombinant full-length human protein was used as the immunogen for the recombinant CDH2 antibody.

This recombinant CDH2 antibody is available for research use only.

Cell surface, cytoplasmic

Protein A affinity chromatography

Human

P19022